Manzo Fabio, Nebbioso Angela, Miceli Marco, Conte Mariarosaria, De Bellis Floriana, Carafa Vincenzo, Franci Gianluigi, Tambaro Francesco P, Altucci Lucia
Dipartimento di Patologia Generale, Seconda Università degli Studi di Napoli, Italy.
Int J Biochem Cell Biol. 2009 Mar;41(3):460-6. doi: 10.1016/j.biocel.2007.12.012. Epub 2007 Dec 28.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor super-family and signals via two death receptors, TRAIL-R1 and TRAIL-R2, and two decoy receptors, TRAIL-R3 and TRAIL-R4, differently expressed in normal and cancer cells. TRAIL is mainly studied for its capacity to induce apoptosis preferentially in cancer cells. TRAIL is expressed in a variety of human tissues, in particular in the lymphoid system, suggesting a strong physiological role in the innate immunity. This review will focus on TRAIL gene structure and regulation, protein folding, tissue expression and molecular signalling. Finally, the potential use of TRAIL as anticancer treatment alone or in combination therapy as well as the use of drugs which signal via TRAIL and its receptors will be analyzed.
肿瘤坏死因子（TNF）相关凋亡诱导配体（TRAIL）是肿瘤坏死因子超家族的成员，通过两种死亡受体TRAIL-R1和TRAIL-R2以及两种诱饵受体TRAIL-R3和TRAIL-R4发出信号，它们在正常细胞和癌细胞中的表达不同。TRAIL主要因其优先诱导癌细胞凋亡的能力而受到研究。TRAIL在多种人体组织中表达，特别是在淋巴系统中，这表明它在先天免疫中具有重要的生理作用。本综述将聚焦于TRAIL的基因结构与调控、蛋白质折叠、组织表达和分子信号传导。最后，将分析TRAIL单独作为抗癌治疗或联合治疗的潜在用途，以及通过TRAIL及其受体发出信号的药物的用途。
